Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lung Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lung Cancer
    Gefitinib Approved in EU for Locally Advanced, Metastatic NSCLC - (DGNews)
    TopAbstracts in Lung Cancer 06/24/2009 - (DGNews)
    TopAbstracts in Lung Cancer 06/10/2009 - (DGNews)
    Prophylactic Cranial Irradiation Has No Impact on Overall Survival in Patients With NSCLC Brain Metastases: Presented at ASCO - (DGDispatch)
    Vandetanib Plus Docetaxel Combination Prolongs Progression-Free Survival in Patients With Non-Small-Cell Lung Cancer: Presented at ASCO - (DGDispatch)

    News archive

     Recent webcasts/CME - Lung Cancer
  • Latest Data From Chicago Provide New Insight Into the Evolving Role of Cytotoxic and Targeted Therapies in Early-Stage NSCLC
  • Silica-Related Lung Disease: It's Still Here

    Webcasts/CME archive

     Recent cases - Lung Cancer
      Diffuse Interstitial Lung Disease Related to Peribronchiolar Metaplasia
      Isolated Pancreatic Metastases from a Bronchogenic Small Cell Carcinoma
      High-Resolution Computed Tomography Illustrating Pulmonary Lymphangitic Carcinomatosis in a Patient with Advanced Pancreatic Cancer: A Case Report
      Mesothelioma in an HIV/AIDS Patient Without History of Asbestos Exposure: Possible Role For Immunosuppression in Mesothelioma: A Case Report
      Pulmonary Lymphoma Mimicking Metastases: A Case Report

      Cases archive
        




      my personal edition > lung cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Gefitinib Demonstrates Efficacy for Treatment of Bronchioloalveolar Lung Cancer: Presented at ASCO

      By M. M. Pennell

      NEW ORLEANS, LA -- June 7, 2004 -- Gefitinib (Iressa) is an effective single-agent treatment for bronchioloalveolar lung cancer (BAC) in both treatment naïve and previously treated patients, according to results presented here June 7th at the American Society of Clinical Oncology 40th Annual Meeting.

      The agent works best in women, patients with no smoking history, and patients who develop an acne-like rash early in treatment, said lead investigator Howard J. West, MD, Medical Oncologist, Swedish Cancer Institute, Seattle, Washington. The median survival in women was 19 months versus 8 months in men and the response rate in women was 20%, while in men the response rate was 13%.

      "Survival among never smokers was especially good -- this group has not yet met median survival, while median survival among smokers was 10 months," he said.

      Rash was a particular strong marker for outcome -- the response rate was 21% among patients with rash and none of the patients with no rash responded, he said. Median survival was 13 months for patients with rash and 5 months for patients with no rash. This response is similar to that reported for other drugs that target the epidermal growth factor receptor (EGFR) pathway, he said.

      Dr. West, who discussed the study at a press conference here June 5th, said the Southwest Oncology Group (SWOG) initiated the study in response to anecdotal reports "about the efficacy of gefitinib in these patients." He noted that BAC "is an unusual cancer but [its incidence] has been rising steadily in recent years, especially among younger women, and there is no standard therapy and minimal response to any therapy."

      The researchers treated 102 treatment naïve patients and 36 who were previously treated.
      Median age of patients was 68 years. Patients received 500 mg of gefitinib until evidence of progression or drug toxicity. Dr. West said the 500 mg dose was selected because the trial was initiated in 2001 "before it was known that 250 mg was the maximum effective dose."

      Among the 69 treatment naïve patients with measurable disease, the response rate was 19%, and 6% had a complete response. Among the 22 previously treated patients with measurable disease the response rate was 9%. The median survival in previously untreated patients was 12 months and in previously treated patients median survival was 13 months, he said.

      The study was funded by AstraZeneca.


      [Presentation title: Gefitinib (ZD1839) Therapy for Advanced Bronchioloalveolar Lung Cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Abstract 7014]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send